SEC Form SC 13G/A filed by PTC Therapeutics Inc. (Amendment)

11/13/23 9:02:39 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PTCT alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 PTC THERAPEUTICS INC COMMON STOCK Cusip #69366J200 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #69366J200 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,431,292 Item 6: 0 Item 7: 6,431,850 Item 8: 0 Item 9: 6,431,850 Item 11: 8.523% Item 12: HC Cusip #69366J200 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 6,431,850 Item 8: 0 Item 9: 6,431,850 Item 11: 8.523% Item 12: IN Item 1(a). Name of Issuer: PTC THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 100 Corporate Court South Plainfield, NJ 07080-2449 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 69366J200 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 6,431,850 (b) Percent of Class: 8.523% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 6,431,850 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of PTC THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of PTC THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 10, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 10, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of PTC THERAPEUTICS INC at October 31, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $PTCT alert in real time by email

Recent Analyst Ratings for

$PTCT

Date	Price Target	Rating	Analyst
5/9/2025	$68.00	Neutral → Buy	BofA Securities
5/7/2025	$40.00	Sell → Neutral	Citigroup
3/11/2025	$41.00 → $55.00	Underperform → Neutral	BofA Securities
3/7/2025	$55.00	Sector Perform	Scotiabank
12/13/2024	$45.00 → $67.00	Equal-Weight → Overweight	Morgan Stanley
12/3/2024	$39.00 → $63.00	Sector Perform → Outperform	RBC Capital Mkts
10/10/2024		Mkt Perform	Raymond James
9/4/2024	$44.00	Outperform	Robert W. Baird

More analyst ratings

SEC Form SC 13G/A filed by PTC Therapeutics Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $PTCT

$PTCT Press Releases

Fastest customizable press release news feed in the world

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

PTC518 PIVOT-HD Study Achieves Primary Endpoint

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$PTCT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

PTC Therapeutics upgraded by BofA Securities with a new price target

PTC Therapeutics upgraded by Citigroup with a new price target

PTC Therapeutics upgraded by BofA Securities with a new price target

$PTCT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Gravier Pierre bought $198,736 worth of shares (7,700 units at $25.81), increasing direct ownership by 30% to 33,700 units (SEC Form 4)

$PTCT SEC Filings

SEC Form 10-Q filed by PTC Therapeutics Inc.

PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$PTCT Financials

Live finance-specific insights

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

PTC518 PIVOT-HD Study Achieves Primary Endpoint

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

$PTCT Leadership Updates

Live Leadership Updates

Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer

$PTCT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $136,656 worth of shares (2,804 units at $48.74), decreasing direct ownership by 1% to 273,234 units (SEC Form 4)

EVP & CHIEF MEDICAL OFFICER Golden Lee Scott sold $42,114 worth of shares (897 units at $46.95), decreasing direct ownership by 1% to 75,997 units (SEC Form 4)

CHIEF BUSINESS OFFICER Pauwels Eric sold $630,104 worth of shares (11,220 units at $56.16), decreasing direct ownership by 13% to 72,640 units (SEC Form 4)

$PTCT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

$PTCT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

Recent Analyst Ratings for
$PTCT

$PTCT
Press Releases

$PTCT
Analyst Ratings

$PTCT
Insider Purchases

$PTCT
SEC Filings

$PTCT
Financials

$PTCT
Leadership Updates

$PTCT
Insider Trading

$PTCT
Large Ownership Changes

$PTCT
FDA approvals